Characteristics and pattern of recurrence after curative surgery in oesophageal cancer

Rodríguez-Camacho, Elena; Pita-Fernández, Salvador; Pértega-Díaz, Sonia; López‐Calviño, Beatriz; Seoane-Pillado, Teresa

doi:10.17235/reed.2015.3748/2015

Cited by 6 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the majority (~90%) of relapses occur within the first 2 years after completion of local therapy, potentially treatable relapses have been reported >5 years after local therapy. 88,89 Metachronous malignancies should also be considered in long-term survivors.…”

Section: Follow-up Long-term Implications and Survivorshipmentioning

confidence: 99%

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Alsina²,

et al. 2022

View full text Add to dashboard Cite

Section: Follow-up Long-term Implications and Survivorshipmentioning

confidence: 99%

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Alsina²,

et al. 2022

View full text Add to dashboard Cite

“…Rodrıǵuez-Camacho et al also found that EC patients who received chemotherapy, radiotherapy, or a combination of both displayed a higher post-recurrence survival rate than palliative care (6.5 months vs. 2.9 months). However, the results were not statistically significant due to the limited sample size (33) (11,38). In the present study, we proved the effectiveness of salvage treatment for ESCC patients, and the targeted therapy and/or immunotherapy was found to be the optimal treatment for ESCC patients after recurrence.…”

mentioning

confidence: 53%

“…Rodríguez-Camacho et al also found that EC patients who received chemotherapy, radiotherapy, or a combination of both displayed a higher post-recurrence survival rate than palliative care (6.5 months vs. 2.9 months). However, the results were not statistically significant due to the limited sample size ( 33 ). Furthermore, Ni et al reported that compared with those only treated with radiotherapy, the median PPS time of ESCC patients increased from 16.2 to 23.2 months after receiving chemoradiotherapy ( 11 ).…”

Section: Discussionmentioning

confidence: 86%

“…With stratified analysis, Sugawara et al revealed that elderly ESCC patients with low BMI had significantly poorer OS than patients with high BMI ( 32 ). Remarkably, EC patients with the recurrence were characterized by a lower BMI as compared to patients without the recurrence ( 33 ). Beyond that, low BMI was also found to be associated with worse PPS of ESCC patients in our work.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Nomogram Model to Predict Post-Progression Survival in Esophageal Squamous Cell Carcinoma Patients With Recurrence After Radical Resection

et al. 2022

View full text Add to dashboard Cite

BackgroundEsophageal squamous cell carcinoma (ESCC) is characterized clinically by frequent recurrence, leading to a poor prognosis after radical surgery. The aim of this study was to identify a prognostic nomogram to predict the post-progression survival (PPS) of ESCC patients based on the features of primary tumor and recurrence.MethodsA total of 234 ESCC patients who underwent recurrence after radical surgery were enrolled in this study. The independent prognostic factors screened by the univariate and multivariate Cox regression analysis were subsequently used to construct a nomogram. The predictive performance of the nomogram was evaluated with the concordance index (C-index), decision curve, and the area under the receiver operating characteristic curve (AUC) and validated in two validation cohorts. The Kaplan-Meier curves of different recurrence patterns were analyzed.ResultsThe prognostic nomogram of PPS was established by integrating independent prognostic factors, including age, body mass index, number of lymph node dissection, recurrence pattern, and recurrence treatment. The nomogram demonstrated good performance, with C-index values of 0.756, 0.817, and 0.730 for the training and two validation cohorts. The 1-year AUC values were 0.773, 0.798, and 0.735 and 3-year AUC values were 0.832, 0.871, and 0.791, respectively. Furthermore, we found that patients with bone metastasis displayed the worst PPS compared to other isolated recurrence patterns.ConclusionWe constructed a nomogram to reliably predict PPS, which would be valuable to provide individual managements for ESCC patients after radical surgery.

show abstract

“…Introducing antitumor drugs, of course, has a direct impact on the development of inflammatory changes in the cancer process [16,17]. Despite the potentially radical surgical treatment of cancer with the appointment of modern chemotherapy and/or radiation therapy, in 40% of patients there is a refund of the disease [18]. The results of 2 randomized studies of various variants of organ-breaching treatment have shown that in patients receiving combined treatment (operation + radiation therapy + chemotherapy), the frequency of local recurrences ranged from 0.3% to 8%, while after only the operations local recurrence ranged from 10% to 34% [19,20].…”

mentioning

confidence: 99%

Impacts of Inflammatory Microenvironment on the Development of Cancer Relapse after Combined Treatment

Movchan¹,

Bagmut²

2021

Ukr. ž. med. bìol. sportu

View full text Add to dashboard Cite

The purpose of the work was to study the impact of certain elements of the inflammatory microenvironment of the tumor on the development of cancer relapse of main localizations with the amplification of ERBB2 after combined treatment. Materials and methods. 80 patients, who had been treated for the period from 2016 to 2021 in National Cancer Institute, Kyiv, Ukraine. They were 42-78 (average 60) years old, ECOG 0-2, female. All patients histologically proved adenocarcinoma GIII-GIV. Everyone was studied for the level of chitinase-like proteins, cryoglobulins, tumor-associated macrophages in the preoperative (with the first identified disease for the first time, prior to the beginning of the neoadjuvant chemotherapy) and in the postoperative period. 1st block: with a confirmed mutation of HER-2/neu gene (amplification ERBB2 (3+)): a) inflammatory breast cancer (primary-edema form) – 10 people, b) diffuse-infiltrative stomach cancer – 10 people; c) diffuse-infiltrative esophagus cancer – 10 people; d) diffuse-infiltrative colorectal cancer – 10 people. 2nd block: without a confirmed mutation of HER-2/neu gene: a) inflammatory breast cancer (primary edema form) – 10 people; b) a diffuse-infiltrative stomach cancer – 10 people; c) diffuse-infiltrative esophageal cancer – 10 people; d) diffuse-infiltrative colorectal cancer – 10 people. Results and discussion. In patients with infiltrative breast cancer, diffuse-infiltrative stomach cancer, and diffuse-infiltrative esophagus cancer, and diffuse-infiltrative colorectal cancer there was a tendency to an increase in the expression of YKL-39 with the ERBB2 amplification during inflammatory tumor infiltration in the stroma. High expression of Stabilin-1 (2.1±0.70, n = 22) was found compared to patient tumors that did not reveal the amplification of ERBB2 (1.46±0.67, n = 13, p = 0.015). In most patients with amplification ERBB2, the cryoglobulin content was average (298.6±2.5 mg/l; 1.3±0.08%) – 20 (50%), which corresponds to cryoglobulinemia type II; with conditioned cryoglobulinemia (79.4±1.01 mg/l) in 10 (25%); high content (477.3±48 mg/l; 3.4±0.2%) was recorded in 10 (25%), which indicates the type III of cryoglobulinemia [the hazard ratio (HR) = 0.71, 95%, сonfidence interval (CI): 0.22-0.83, p = 0.005] Conclusion. Amplification of ERBB2 and macrophages surroundings markers CD68, M2 subpopulation RS1 (Stabilin-1), chitinase-like proteins YKL-39 and SI-CLP independently identified subgroups of patients with inflammatory breast cancer, diffuse stomach and diffuse esophageal, diffuse colorectal cancer with a bad forecast. In patients with the presence of the amplification of ERBB2 in the inflammatory tumor infiltrate, in the stroma, the higher expression of the chitinase-like protein YKL-39 and M2-polarization RS1 of the marker Stabilin-1, was detected compared to the patient's tumors without amplifying ERBB2. This study shows an important role of quantitative values associated with the tumor phenotype and macrophages in tumor progression, depending on the presence of ERBB2 gain. In patients with cryoglobulinemia with inflammatory cancer the secondary immunodeficiency is developed. This is determined by anomalies in the cell and humoral immune system, and leads to the development of postoperative inflammatory complications and relapses

show abstract

Characteristics and pattern of recurrence after curative surgery in oesophageal cancer

Cited by 6 publications

References 18 publications

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

A Nomogram Model to Predict Post-Progression Survival in Esophageal Squamous Cell Carcinoma Patients With Recurrence After Radical Resection

Impacts of Inflammatory Microenvironment on the Development of Cancer Relapse after Combined Treatment

Contact Info

Product

Resources

About